Composition for treating acne and preparation method thereof

Abstract

The invention belongs to the technical field of skin care products, and particularly relates to a composition for treating acne and a preparation method thereof. The composition comprises the following components: 1-2% of a lactobacillus fermentation product and 5-8% of a plant extract component, the plant extraction component consists of a Pinus densiflora leaf extract, a celery root extract and an aster extract. The mass ratio of the Pinus densiflora leaf extract to the apium graveolens root extract to the aster extract is 1: (1-3): (5-10). Wherein the apium graveolens root extract, the Pinus densiflora leaf extract and the aster extract have a certain synergistic effect in the formula of the composition, so that the composition for treating acne provided by the invention can effectively inhibit the growth of propionibacterium acnes, reduce the occurrence of skin inflammation and effectively treat acne, and has a relatively good market application prospect.

Description

Technical Field

[0001] The present invention belongs to the technical field of skin care products, and particularly relates to a composition for treating acne and a preparation method thereof. Background Art

[0002] Acne, as a chronic inflammatory skin disease involving hair follicles and sebaceous glands, is prevalent in adolescents and young people. Its pathological mechanism mainly involves the synergistic action of multiple factors such as abnormal keratinization of hair follicle ducts, hyperfunction of sebaceous glands, and microbial colonization. The clinical manifestations are diverse skin lesions such as comedones, papules, and cysts in sebaceous gland-rich areas such as the face, chest, and back. The prolonged course can lead to scar formation and psychological disorders, seriously affecting the quality of life of patients.

[0003] Microbiota dysbiosis is one of the core links in the pathogenesis of acne, and the gram-positive anaerobic bacterium Propionibacterium acnes is recognized as a key pathogenic bacterium. This bacterium secretes extracellular enzyme systems such as lipase, protease, and hyaluronidase, catalyzing the decomposition of sebum triglycerides into free fatty acids that promote keratinization, and at the same time inducing the release of pro-inflammatory factors (such as IL-1β, TNF-α), exacerbating follicular epithelial hyperkeratinization and local inflammatory responses. In addition, the commensalism of Staphylococcus spp. and Malassezia furfur may also synergistically aggravate the condition.

[0004] Currently, topical anti-acne cosmetics have been widely used as non-invasive prevention and treatment means. However, the existing product formulations mostly rely on chemically synthesized bactericides (such as benzoyl peroxide, triclosan) and keratolytic agents (such as salicylic acid). Although they can inhibit the proliferation of pathogenic bacteria and dredge hair follicles in the short term, long-term use is likely to cause skin barrier function damage, erythema, desquamation and other irritating reactions. In addition, the abuse of antibiotic components may lead to the spread of drug-resistant Propionibacterium acnes strains.

[0005] Therefore, developing products containing natural-source anti-acne active ingredients with both high antibacterial activity and low skin irritation has become an urgent technical problem in the fields of dermatology and cosmetics. Summary of the Invention

[0006] To overcome the deficiencies of the prior art, the purpose of the present invention is to provide a composition containing plant extracts and probiotic metabolites of natural and biogenic active ingredients, which can replace traditional chemically synthesized bactericides, reduce the risk of damage to the skin barrier, reduce adverse reactions such as erythema and desquamation, and this composition can effectively inhibit the growth of Propionibacterium acnes, has anti-inflammatory and soothing effects, and has a significant acne treatment effect.

[0007] To achieve the above purpose, the present invention discloses the following technical solutions:

[0008] In the first aspect, the present invention provides a composition for treating acne. Calculated by mass percentage, the composition contains the following components:

[0009] 1 - 2% of Lactobacillus fermentation product;

[0010] 5 - 8% of plant extract components;

[0011] The plant extract components are composed of Pinus sylvestris leaf extract, Apium graveolens root extract and Aster tataricus extract.

[0012] Preferably, the mass ratio of the Pinus sylvestris leaf extract, Apium graveolens root extract to Aster tataricus extract is 1:(1 - 3):(5 - 10).

[0013] Preferably, the composition further comprises the following components:

[0014] Base oil, salicylic acid, emulsifier, chelating agent, humectant, preservative, solvent.

[0015] More preferably, the addition amount of the base oil in the composition is 1 - 2 wt%;

[0016] The base oil is selected from at least one of isononyl isononanoate, caprylic / capric triglyceride, and coco-caprylate / caprate.

[0017] More preferably, the addition amount of salicylic acid in the composition is 0.1 - 0.2 wt%.

[0018] More preferably, the addition amount of the emulsifier in the composition is 0.1 - 0.3 wt%;

[0019] The emulsifier is selected from at least one of coco-glucoside, polyglyceryl-6 behenate, and PEG-100 stearate.

[0020] More preferably, the addition amount of the chelating agent in the composition is 0.01 - 0.02 wt%;

[0021] The chelating agent is selected from disodium EDTA

[0022] More preferably, the addition amount of the humectant in the composition is 1 - 5 wt%;

[0023] The addition amount of the preservative in the composition is 0.1 - 0.5 wt%;

[0024] The humectant is selected from at least one of glycerol, 1,3-propanediol, and butanediol;

[0025] The preservative is selected from at least one of p-hydroxyacetophenone, octanoyl hydroxamic acid, and ethylhexylglycerin.

[0026] More preferably, the solvent in the composition is deionized water.

[0027] In a second aspect, the present invention provides a method for preparing the composition for treating acne described in the first aspect, comprising the following steps:

[0028] Step 1. Stir an emulsifier and a base oil evenly at 80 - 90 °C and 300 - 500 r / min to obtain Solution A;

[0029] Step 2. Stir a preservative, a chelating agent, a humectant and deionized water evenly at 80 - 90 °C and 300 - 500 r / min to obtain Solution B;

[0030] Step 3. At 80 - 90 °C, add Solution A to Solution B, first homogenize and disperse at 10000 - 15000 r / min for 10 - 15 min, and then stir at 200 - 300 r / min for 40 - 50 min to obtain Mixture C;

[0031] Step 4. After cooling Mixture C to 45 - 50 °C, sequentially add a Lactobacillus fermentation product, a plant extract component, and salicylic acid, and stir at 200 - 300 r / min for 13 - 20 min to obtain the composition for treating acne.

[0032] In the present invention:

[0033] The extract of Pinus sylvestris leaves inhibits the proliferation of Propionibacterium acnes through terpenoids (such as α-pinene) and polyphenols, reducing the key pathogenic bacteria causing acne; flavonoid components (such as quercetin) and pinoresinol can regulate inflammatory signaling pathways (such as NF-κB), reducing the release of pro-inflammatory factors (IL-6, TNF-α), and alleviating redness and inflammatory reactions; at the same time, antioxidant components such as proanthocyanidins can neutralize free radicals, reduce oxidative stress damage, and promote skin repair to reduce acne marks. In addition, its potential astringency and trace elements may assist in regulating sebum secretion and improving pore blockage.

[0034] The extract of Apium graveolens root is rich in flavonoid compounds (such as apigenin), which can inhibit the release of inflammatory factors such as IL-6 and TNF-α, and reduce skin inflammatory reactions by regulating signaling pathways such as NF-κB, helping to relieve symptoms such as redness and pain caused by acne. The flavonoid compounds in the extract of Apium graveolens root also have significant antioxidant capacity, can scavenge free radicals, reduce the damage of oxidative stress to the skin, promote skin metabolism and repair the barrier, and accelerate the fading of acne marks.

[0035] The aster root extract mainly contains compounds such as flavonoids, triterpenoids, and steroids. It has antioxidant effects, can scavenge free radicals, reduce damage to skin cells, and delay aging; it has anti-inflammatory effects, can reduce skin inflammatory reactions, and relieve redness, swelling, and itching; it has moisturizing effects, helps the skin lock in moisture, and improves dryness and peeling problems; it has antibacterial effects, can inhibit the growth of harmful bacteria on the skin surface, and prevent acne and skin infections; as a skin protectant, it can isolate the damage of the external environment to the skin and enhance the skin's barrier function.

[0036] Advantages of the present invention:

[0037] 1. The apium graveolens root extract, pinus sylvestris leaf extract, and aster root extract in the composition of the present invention can produce a synergistic effect in the treatment of acne; enabling the provided acne treatment composition to effectively inhibit the growth of propionibacterium acnes, reduce the occurrence of skin inflammation, and thus effectively treat acne.

[0038] 2. The acne treatment composition provided by the present invention can promote the metabolism of the skin cutin layer, improve the facial luster, repair the skin damaged by acne, and has significant effects of removing acne, inhibiting acne, antibacterial, and anti-inflammatory. Detailed implementation manners

[0039] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. Those skilled in the art should understand that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0040] Unless otherwise specified, the test methods used in the examples and comparative examples are all conventional methods; the materials, reagents, etc. used, unless otherwise specified, can all be obtained from commercial channels; the percentages mentioned in the examples and comparative examples, unless otherwise specified, are all mass percentages.

[0041] In the present invention:

[0042] Lactobacillus fermentation product: Purchased from Guangzhou Huayang Biotechnology Co., Ltd.;

[0043] Pinus sylvestris leaf extract: Purchased from Shenzhen Regent Biotechnology Co., Ltd.;

[0044] Apium graveolens root extract: Purchased from New Tianyu Biotechnology Co., Ltd.;

[0045] Aster root extract: Purchased from Xinyanghe Biotechnology Co., Ltd.

[0046] Preparation of the acne treatment composition:

[0047] Accurately weigh according to the mass percentages of the raw materials in Table 2;

[0048] Step 1. Stir the emulsifier and the base oil evenly at 80 - 90 °C and 300 - 500 r / min to obtain Solution A;

[0049] Step 2. Stir the preservative, the chelating agent, the humectant and deionized water evenly at 80 - 90 °C and 300 - 500 r / min to obtain Solution B;

[0050] Step 3. At 80 - 90 °C, add Solution A to Solution B, first homogenize and disperse at 10000 - 15000 r / min for 10 - 15 min, and then stir at 200 - 300 r / min for 40 - 50 min to obtain Mixture C;

[0051] Step 4. After cooling Mixture C to 45 - 50 °C, add the Lactobacillus fermentation product, the plant extract component and salicylic acid in sequence, and stir at 200 - 300 r / min for 13 - 20 min to obtain the acne - treating composition.

[0052] The plant extract component is compounded according to the mass ratio in Table 1:

[0053] Table 1 Mass ratio of raw materials of the plant extract component

[0054]

[0055] Note: " / " in the table means no addition.

[0056] Table 2 Each raw material component and its mass percentage of the acne - treating composition

[0057]

[0058] Note: " / " in the table means no addition.

[0059] To verify the influence of the key components in the examples on the acne - removing and acne - suppressing performance of the overall formula, the components are defaulted or the ratios are adjusted on the basis of the formula in Example 3, as follows:

[0060] Table 3 Each raw material component and its mass percentage of the comparative - example composition

[0061]

[0062]

[0063] Performance test

[0064] 1 Sample stability test:

[0065] 1. Heat resistance test: Adjust the constant temperature incubator to 40°C. Take the 4 examples and 5 comparative examples prepared above as 9 test samples respectively. Take three of each test sample and place them in transparent glass bottles, with a sample loading of 20 ml / bottle. After sealing, place them in the constant temperature incubator. Take them out after three months, restore them to room temperature, and observe the appearance changes.

[0066] 2. Cold resistance test: Adjust the constant temperature incubator to -10°C. Take the 4 examples and 5 comparative examples prepared above as 9 test samples respectively. Take three of each test sample and place them in transparent glass bottles, with a sample loading of 20 ml / bottle. After sealing, place them in the constant temperature incubator. Take them out after three months, restore them to room temperature, and observe the appearance changes.

[0067] 3. Normal temperature test: Take the 4 examples and 5 comparative examples prepared above as 9 test samples respectively. Take three of each test sample and place them in transparent glass bottles, with a sample loading of 20 ml / bottle. After sealing, place them at normal temperature for 6 months, and then observe the appearance changes of the samples.

[0068] No precipitation, sedimentation and other phenomena were observed in the heat resistance test, cold resistance test and normal temperature test, and the original appearance was maintained.

[0069] 2 Human skin patch test:

[0070] Conduct a human skin closed patch test according to the human skin patch test specified in the "Technical Specifications for Cosmetics Safety".

[0071] 2.1 Test purpose: To detect the potential possibility of the test substance causing adverse reactions on human skin.

[0072] 2.2 Test design: Apply the patch tester with the test substance to the back skin of the subject for 24 h. Score the skin according to the skin reaction grading standard of the skin closed patch test at 30 min (after the indentation disappears), 24 h, and 48 h respectively after removing the patch tester with the test substance.

[0073] 2.3 Test substance: The compositions prepared in Examples 1-4 and Comparative Examples 1-5.

[0074] 2.4 Test method:

[0075] Requirements for volunteers: Select volunteers aged 18-60 who meet the test requirements as the test subjects, randomly divide them into groups, with 30 people in each group;

[0076] Test steps: Select a qualified patch test device with an area not exceeding 50 mm 2 and a depth of about 1 mm. Put the test substance into the small chamber of the patch tester, with a dosage of about 0.02 mL - 0.025 mL. Apply the patch tester with the test substance to the back of the subject with a low-allergy tape, and gently press it with the palm to make it evenly adhere to the skin for 24 h.

[0077] At 30 min (after the indentation disappeared), 24 h, and 48 h respectively after removing the test substance patch tester, observe the skin reaction according to the criteria in Table 4 and record the observation results. The results are shown in Table 5.

[0078] Table 4 Grading criteria for skin reactions in skin occlusive patch test

[0079]

[0080] Table 5 Results of human safety test

[0081]

[0082]

[0083] In vitro inhibitory test of the sample against Propionibacterium acnes:

[0084] Test samples: Examples 1 - 4 and Comparative Examples 1 - 5.

[0085] Select the 3rd generation of Propionibacterium acnes (ATCC6919) as the test strain, and conduct the antibacterial test according to "5.1.2 Carrier immersion quantitative antibacterial test" in WS / T 650—2019 "Evaluation methods for antibacterial and bacteriostatic effects".

[0086] Absorb 10 μL of the bacterial suspension (5.0×10 6 ~5.0×10 7 CFU / mL) onto the sterilized carrier and let it dry at room temperature for later use. Weigh the test sample at a dose of 5 g / tablet into a sterile petri dish and place it in a 20°C water bath for 5 min. Immerse the contaminated carrier completely in the sample and start timing immediately. After acting for 15 min and 30 min respectively, take each contaminated carrier and add it to 5.0 mL of PBS buffer for oscillation to wash down the test bacteria. Then, respectively absorb 1.0 mL of the sample solution and determine the number of viable bacteria according to the viable bacteria culture counting method. Inoculate 2 petri dishes with each tube of the sample solution. Place all the above petri dishes at 37°C and anaerobically culture for 72 h to observe the results. At the same time, a positive control group needs to be set up when measuring each test sample (the positive controls for each group are the corresponding formulations of Examples 1 - 4 and Comparative Examples 1 - 5 lacking lactic acid bacteria fermentation products and plant extracts). Repeat the test 3 times and calculate the antibacterial rate (X) according to formula (1). The results are shown in Table 6.

[0087]

[0088] In the formula:

[0089] G0: The average total number of colonies in the positive control group, CFU / tablet;

[0090] G1: The average total number of colonies in the sample group, CFU / tablet.

[0091] Table 6 Antibacterial Results

[0092]

[0093] Anti-inflammatory Performance Test

[0094] Test Substances: Compositions prepared in Examples 1-4 and Comparative Examples 1-5, Dexamethasone.

[0095] Stimulating macrophages with LPS is a classic cell model for studying inflammatory pathways. By comparing the differences in the contents of pro-inflammatory factors TNF-α and IL-1β secreted by macrophages in the negative control group and the sample group, the anti-inflammatory level of the test substances was evaluated.

[0096] Before the test, through cytotoxicity detection (MTT method), a cell viability ≥ 90% was selected as the safe range of the test substances, and the safe administration concentration of the test substances in the experiment was determined as the working concentration (the unified working concentration of the examples and comparative examples was 3 mg / mL, and that of dexamethasone was 100 μg / mL).

[0097] The resuscitated mouse macrophages were inoculated into a 6-well plate and placed in an incubator (37 °C, 5 v / v% CO 2 ) and cultured for 24 h, then the old cell culture medium in the wells was aspirated and discarded.

[0098] Sample Group: 2 mL of cell culture medium containing the compositions prepared in Examples 1-4 and Comparative Examples 1-5 at the working concentration was added to each well;

[0099] Negative Control Group: 2 mL of cell culture medium without any test substances was added to each well;

[0100] Positive Control Group: 2 mL of cell culture medium containing dexamethasone at the safe administration concentration was added to each well;

[0101] After administration, the 6-well plates of the above different groups were placed in an incubator and cultured for 2 h, then 200 μL of working solution containing 1 μg / mL lipopolysaccharide (LPS) was added to each well of each group and cultured for another 22 h.

[0102] After the incubation ended, the cell culture medium was collected and the contents of IL-1β and TNF-α were detected according to the instructions of the ELISA kit. Each group of experiments was repeated 3 times, and the average value was taken. The inhibition rates of IL-1β and TNF-α were calculated according to formula (2), and the results are shown in Table 7.

[0103]

[0104] In the formula:

[0105] S: Inhibition rate of IL-1β / TNF-α;

[0106] T0: Average content of IL-1β / TNF-α in the negative control group

[0107] T1: Average content of IL-1β / TNF-α in the group with added medicine (sample or positive control)

[0108] Table 7 Anti-inflammatory performance test

[0109]

[0110]

[0111] Conclusion analysis:

[0112] According to the data in Table 7, the positive control group has the best effect, indicating that the experimental method is effective. The inhibition rates of IL-1β and TNF-α in Example 3 are higher than those of other examples and comparative examples, which shows that the formulation of Example 3 performs optimally in terms of anti-inflammation. The plant extract components in Comparative Examples 1-3 lack Apium graveolens root extract, Pinus sylvestris leaf extract, and Aster tataricus extract respectively. The results show that the antibacterial and anti-inflammatory effects of Comparative Examples 1-3 are significantly worse, and the inhibition rate of inflammatory factors in Comparative Example 2 is the lowest, indicating that Apium graveolens root extract, Pinus sylvestris leaf extract, and Aster tataricus extract have a synergistic effect in the overall formulation.

[0113] In Comparative Examples 4 and 5, the mass ratios of Apium graveolens root extract, Pinus sylvestris leaf extract, and Aster tataricus extract are not within the preferred mass ratio range of the present invention. The results show that the inhibition rates of inflammatory factors in Comparative Examples 4 and 5 are lower than those of Examples 1-4 but higher than those of Comparative Examples 1-3, reflecting that although the proportions of the three plant extract components are adjusted, the effect of the composition retaining the three components is still superior to that of the composition lacking components. However, their inhibition rates of IL-1β and TNF-α are significantly lower than those of the examples, indicating that the mass ratio among Apium graveolens root extract, Pinus sylvestris leaf extract, and Aster tataricus extract also plays an important role in the overall formulation.

[0114] Human efficacy test

[0115] Test subjects: 54 male volunteers with obvious acne on both sides of the face, in the neonatal or inflammatory period, and with facial skin belonging to the acne-prone type were recruited. There were 6 people in each group, aged 20-35 years. Subjects were excluded if they used immunosuppressive agents or antihistamines, had used other facial acne treatment products within one month, had severe systemic diseases and were currently on systemic medications, or were sensitive to drugs.

[0116] Samples to be tested: Compositions prepared in Examples 1-4 and Comparative Examples 1-5.

[0117] Detection process: Five days before the start of the detection, products with similar functions should be discontinued. After the start of the detection, after facial cleansing in the morning and evening every day, apply toner, and then use 5 ml of the sample and evenly apply it on the face for 28 consecutive days.

[0118] 1. Facial microbial activity

[0119] Porphyrin is a substance secreted by Propionibacterium acnes. The number of porphyrin fluorescence can indirectly reflect the number of Propionibacterium acnes. Collect images of the detection object's face through VISIA, use image analysis software to analyze the porphyrin value of the face, and record the values on the 1st day and the 28th day.

[0120] Calculation formula for ΔT: ΔT = T 28 -T 1

[0121] T 28 : The average porphyrin value of each group on the 28th day;

[0122] T 1 : The average porphyrin value of each group on the 1st day.

[0123] 2. Skin heme content

[0124] The E value in the skin represents the heme content in the skin. The larger the E value in the acne area, the more severe the inflammation at the acne site, and vice versa, the lighter the inflammation. Use the MX18 heme test probe of German CK company to measure the face of the detection object, and record the values on the 1st day and the 28th day.

[0125] Calculation formula for ΔE: ΔE = E 28 -E 1

[0126] E 28 : The average E value of each group on the 28th day;

[0127] E 1 : The average E value of each group on the 1st day.

[0128] The results of the human efficacy test are shown in Table 8.

[0129] Table 8 Results of the human efficacy test

[0130]

[0131] Analysis of test results:

[0132] As can be seen from Table 8, the inhibitory effects of Examples 1-4 on Propionibacterium acnes are significantly better than those of Comparative Examples 1-5, indicating that the acne treatment composition provided by the present invention has excellent ability to inhibit Propionibacterium acnes; compared with Comparative Examples 1-5, Example 3 has significantly better antibacterial effect than the latter, indicating that the addition of the plant extract components in the acne treatment composition, namely Pinus sylvestris leaf extract, Apium graveolens root extract, and Aster tataricus extract, and their specific mass ratio have a synergistic effect in antibacterial and anti-inflammatory aspects.

[0133] According to the results of human efficacy tests, it can be seen that the acne treatment composition provided by the present invention can effectively inhibit the growth of skin epidermal bacteria, reduce the occurrence of skin inflammation. Satisfaction inquiries were made to the subjects using the products of Examples 1-4. The subjects stated that there was no discomfort on the face after 28 days of using the products, the facial itching was significantly improved, the luster was enhanced, the acne marks became lighter, and the acne inflammation subsided significantly. This result proves that the acne treatment composition provided by the present invention can promote the metabolism of the skin cutin layer, improve the facial luster, repair the acne-damaged skin, and has significant effects of removing acne, inhibiting acne, antibacterial, and anti-inflammatory.

[0134] Finally, it should be noted that the above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments, or perform equivalent replacements on some of the technical features. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. A composition for treating acne, characterized in that: The composition comprises the following components in percentage by mass: Lactobacillus fermentation products 1-2%; Plant extract components 5-8%; The plant extract component consists of European red pine leaf extract, celery root extract and aster extract.

2. The composition for treating acne according to claim 1, characterized in that: The mass ratio of the European red pine leaf extract, the celery root extract and the aster extract is 1:(1-3):(5-10).

3. The composition for treating acne according to claim 1, characterized in that: The composition also comprises the following components: Basic oils, salicylic acid, emulsifiers, chelating agents, moisturizers, preservatives, solvents.

4. The composition for treating acne according to claim 3, characterized in that: The amount of base oil added to the composition is 1-2wt%; The base oil is selected from at least one of isononyl isononanoate, caprylic / capric triglyceride, and coconut oil caprylate / caprate.

5. The composition for treating acne according to claim 3, characterized in that: The added amount of salicylic acid in the composition is 0.1-0.2 wt %.

6. The composition for treating acne according to claim 3, characterized in that: The amount of emulsifier added to the composition is 0.1-0.3wt%; The emulsifier is selected from at least one of coco-glucoside, polyglyceryl-6 behenate, and PEG-100 glyceryl stearate.

7. The composition for treating acne according to claim 3, characterized in that: The amount of the chelating agent added to the composition is 0.01-0.02 wt %; The chelating agent is selected from disodium EDTA.

8. The composition for treating acne according to claim 3, characterized in that: The amount of the moisturizer added to the composition is 1-5wt%; The amount of preservative added to the composition is 0.1-0.5wt%; The moisturizer is selected from at least one of glycerol, 1,3-propylene glycol, and butylene glycol; The preservative is selected from at least one of p-hydroxyacetophenone, caprylhydroxamic acid and ethylhexylglycerin.

9. The composition for treating acne according to claim 3, characterized in that: The solvent in the composition is deionized water.

10. The method for preparing the composition for treating acne according to claim 3, characterized in that: The following steps are involved: Step 1. Stir the emulsifier and base oil at 80-90°C and 300-500r / min to obtain solution A; Step 2. Stir the preservative, chelating agent, moisturizing agent and deionized water at 80-90° C. and 300-500 r / min to obtain solution B; Step 3. At 80-90° C., solution A is added to solution B, firstly homogenized and dispersed at 10000-15000 r / min for 10-15 min, and then stirred at 200-300 r / min for 40-50 min to obtain a mixture C; Step 4. After cooling the mixture C to 45-50° C., add the lactobacillus fermentation product, the plant extract component and salicylic acid in sequence, and stir at 200-300 r / min for 13-20 min to obtain the composition for treating acne.

Images